CMPX
Compass Therapeutics, Inc. [CMPX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CMPX Stock Summary
Top CMPX Correlated Resources
CMPX
Top 10 Correlated ETFs
CMPX
Top 10 Correlated Stocks
CMPX
In the News
CMPX Financial details
Company Rating
-
Market Cap
206.53M
Income
-37.51M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
21 Mar 2024
P/E
-6.56
Forward P/E
-
PEG
0.86
P/S
-
P/B
1.54
P/C
-
P/FCF
-6.31
Quick Ratio
17.94
Current Ratio
18.26
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.31
EPS next Y
-
EPS next Q
-
EPS this Y
-73.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-12.13%
-
-
-
-
SMA20
-26.67%
SMA50
15.79%
SMA100
27.17%
Inst Own
-
Inst Trans
-
ROA
-22%
ROE
-22%
ROC
-0.3%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.15-3.62
52W High
-33.67%
52W Low
+99%
RSI
32.34
Rel Volume
1.74
Avg Volume
395.31K
Volume
689.1K
Perf Week
-11.95%
Perf Month
-42.32%
Perf Quarter
4.74%
Perf Half Y
5.85%
-
-
-
-
Beta
0.571
-
-
Volatility
0.13%, 0.38%
Prev Close
-5.24%
Price
1.99
Change
-1.49%
Company Profile
- Volume Average 395.31K
- Market Capitalization 206.53M
- Employee 26
- CEO Dr. Vered Bisker-Leib M.D., MBA, Ph.D.
- Headquarters Boston,MA,US
- IPO Date 2021-04-05
-
Website
https://www.compasstherapeutics.com 
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
